Turkey Country Drug Report 2019

Drug-related infectious diseases

In Turkey, information on human immunodeficiency virus (HIV) infection is provided by the Public Health Agency of the Ministry of Health and the Directorate-General for Health Services of the Ministry of Health and is complemented by the results of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV testing among people who inject drugs (PWID) who have been admitted to specialised treatment centres.

Prevalence of HIV and HCV antibodies among people who inject drugs in Turkey (%)
  Region HCV HIV
Data from 2015 (HIV) and from 2017 (HCV).
  National 45.77 0
  Sub-national : :

The available data indicate that there were 14 newly diagnosed cases of HIV infection linked to injecting drug use in 2017, corresponding to 1 % of new cases with information on the route of transmission. None of the almost 3 000 drug treatment clients who were tested in 2015 was HIV positive, while 4 out of 10 treatment clients tested positive for HCV antibodies.

The prevalence of HBV infection among PWID who are in treatment is within the range of HBV prevalence among the general population: around 3 % of females and 4 % of males are HBV positive.

Turkey main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.